Checkpoint Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CKPT research report →
Companywww.checkpointtx.com
Checkpoint Therapeutics, Inc. , clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.
- CEO
- James F. Oliviero III,
- IPO
- 2016
- Employees
- 24
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $367.72M
- P/E
- -0.06
- P/S
- 0.00
- P/B
- 0.16
- EV/EBITDA
- -8.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -2185.94%
- ROIC
- -245.34%
Growth & Income
- Revenue
- $41.00K · -60.19%
- Net Income
- $-56,240,000 · -8.47%
- EPS
- $-1.42 · 48.74%
- Op Income
- $-56,174,000
- FCF YoY
- 34.65%
Performance & Tape
- 52W High
- $4.50
- 52W Low
- $1.80
- 50D MA
- $4.09
- 200D MA
- $3.33
- Beta
- 1.14
- Avg Volume
- 3.08M
Get TickerSpark's AI analysis on CKPT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 29, 25 | Fortress Biotech, Inc. | sell | 100,000 |
| May 30, 25 | Fortress Biotech, Inc. | sell | 6,122,249 |
| May 30, 25 | Fortress Biotech, Inc. | sell | 700,000 |
| May 29, 25 | WEISS MICHAEL S | other | 50,000 |
| May 28, 25 | WEISS MICHAEL S | other | 12,195 |
| May 30, 25 | WEISS MICHAEL S | other | 187,007 |
| May 28, 25 | SALZMAN BARRY M | other | 12,195 |
| May 30, 25 | SALZMAN BARRY M | other | 147,007 |
| May 29, 25 | ROSENWALD LINDSAY A MD | other | 50,000 |
| May 28, 25 | ROSENWALD LINDSAY A MD | other | 12,195 |
Our CKPT Coverage
We haven't published any research on CKPT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CKPT Report →